Q'Apel Medical Launches Lynx™ Aspiration Catheter for Stroke Treatment in the U.S.

Q'Apel Medical Launches Lynx™ Aspiration Catheter System in the U.S.

In a significant advancement for neurovascular interventions, Q'Apel Medical has launched its Lynx™ Aspiration Catheter System in the United States. This new catheter system is specifically engineered to aid medical professionals in efficiently performing mechanical thrombectomies, a critical procedure for treating patients with acute ischemic strokes caused by vessel blockages.

Addressing Complex Challenges in Stroke Treatment

As medical technology evolves, the demand for innovative solutions that allow for effective access and retrieval of blood clots amidst increasingly complex anatomical structures intensifies. The Lynx™ Aspiration Catheter System is designed to meet these demands, providing healthcare providers with tools that enhance both efficiency and precision during crucial treatment timelines.

Dr. Kaustubh Limaye, a prominent neurologist at Indiana University School of Medicine, praises the system: "Each stroke case presents unique anatomical challenges. My goal is to conduct the quickest and safest thrombectomy possible for every patient. The Lynx aspiration catheter system features three highly trackable catheters that enhance my ability to respond to these challenges with agility and precision. In stroke management, where time is of the essence, the right choice in catheter selection can make all the difference.”

Innovative Technology Behind the Lynx™ System

The Lynx™ Aspiration Catheter is the second product utilizing Q'Apel's proprietary Q'Apel Laser Cut Tube (QLCT™) technology. This system incorporates a sophisticated bimetal shaft that balances the required support with flexible navigation, an essential characteristic for accessing complex cerebrovascular paths. The innovative design features an open-spaced nitinol structure, which significantly improves kink resistance and structural resilience—key attributes that help maintain catheter lumen patency and effective force transmission.

Versatility and Compatibility

The Lynx platform boasts multiple inner diameter sizes—ranging from 0.044-inch to 0.072-inch—facilitating optimal vessel-to-catheter ratios as well as compatibility across both small and larger calibers. This versatility is crucial for a wide range of procedural needs and caters to the varying anatomies present in stroke patients.

Q'Apel’s CTO, Jeff Krolik, emphasized the importance of this product launch, stating, “Lynx marks an important step forward for Q'Apel, extending our proprietary QLCT technology into aspiration and bringing its precision advantages to the urgent demands of stroke thrombectomy. The Lynx represents our commitment to continually innovating our neurovascular portfolio and tackling real-world procedural hurdles that medical professionals face.”

A Commitment to Quality Patient Care

As the Lynx™ Aspiration Catheter System gains FDA clearance, Q'Apel Medical continues its mission to enhance neurovascular care. Their focus is not only on providing cutting-edge products, but also on supporting healthcare professionals with innovative solutions tailored to improve patient outcomes.

With the Lynx™ system now commercially available, Q'Apel is set to significantly impact stroke treatment strategies across the country. This innovation stands as a testament to the company's dedication to pushing the boundaries of medical technology in pursuit of excellence in patient care. For additional information about Q'Apel Medical and their offerings, please visit www.qapelmedical.com.